164 related articles for article (PubMed ID: 12211096)
21. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
[TBL] [Abstract][Full Text] [Related]
22. [Risperidone].
Zolk O; Thürauf N
Dtsch Med Wochenschr; 2003 Jun; 128(24):1353-6. PubMed ID: 12802745
[No Abstract] [Full Text] [Related]
23. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
24. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
Ding JJ; Jiao Z; Yu YQ; Shi XJ
Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2014 Oct; 31(10):2605-17. PubMed ID: 24792824
[TBL] [Abstract][Full Text] [Related]
27. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.
Regenthal R; Kunstler U; Hesse S; Sabri O; Preiss R
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):370-8. PubMed ID: 16119512
[TBL] [Abstract][Full Text] [Related]
28. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
[TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.
Titier K; Déridet E; Moore N
Toxicol Appl Pharmacol; 2002 Apr; 180(2):145-9. PubMed ID: 11969382
[TBL] [Abstract][Full Text] [Related]
30. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
32. [Extrapyramidal syndrome].
Nakagawa S; Koyama T
Ryoikibetsu Shokogun Shirizu; 2003; (38):179-82. PubMed ID: 12876960
[No Abstract] [Full Text] [Related]
33. Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients.
Gassó P; Mas S; Oliveira C; Bioque M; Parellada E; Bernardo M; Trias G; Comeche J; Lafuente A
Eur Neuropsychopharmacol; 2011 Apr; 21(4):294-9. PubMed ID: 20619616
[TBL] [Abstract][Full Text] [Related]
34. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.
Kapur S; VanderSpek SC; Brownlee BA; Nobrega JN
J Pharmacol Exp Ther; 2003 May; 305(2):625-31. PubMed ID: 12606608
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology of antipsychotic drug-induced movement disorders.
Casey DE
J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Voicu V; Medvedovici A; Ranetti AE; Rădulescu FŞ
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):955-68. PubMed ID: 23600946
[TBL] [Abstract][Full Text] [Related]
37. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
Gassó P; Mas S; Bernardo M; Alvarez S; Parellada E; Lafuente A
Pharmacogenomics J; 2009 Dec; 9(6):404-10. PubMed ID: 19506579
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
[TBL] [Abstract][Full Text] [Related]
39. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
40. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]